Advanced

Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes

Sugihara, Hitoshi; Nagao, Mototsugu LU ; Harada, Taro; Nakajima, Yasushi; Tanimura-Inagaki, Kyoko; Okajima, Fumitaka; Tamura, Hideki; Inazawa, Takeshi; Otonari, Takatoshi and Kawakami, Masanobu, et al. (2014) In Journal of Diabetes Investigation 5(2). p.206-212
Abstract

Aims/Introduction: α-Glucosidase inhibitors (αGIs) are widely used for the primary treatment of type 2 diabetes. We compared the clinical effects of three αGIs (miglitol, acarbose and voglibose) in patients with obese type 2 diabetes. Materials and Methods: Japanese patients (n = 81) with obese type 2 diabetes (body mass index [BMI] ≥25 kg/m2) were enrolled in this multicenter, open-label study. The participants were randomized into the miglitol (n = 18), acarbose (n = 22), voglibose (n = 19) or control (n = 22) groups. Glycemic control (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, BMI, serum insulin, serum lipids (low-density lipoprotein and high-density lipoprotein cholesterol, and triacylglycerols)... (More)

Aims/Introduction: α-Glucosidase inhibitors (αGIs) are widely used for the primary treatment of type 2 diabetes. We compared the clinical effects of three αGIs (miglitol, acarbose and voglibose) in patients with obese type 2 diabetes. Materials and Methods: Japanese patients (n = 81) with obese type 2 diabetes (body mass index [BMI] ≥25 kg/m2) were enrolled in this multicenter, open-label study. The participants were randomized into the miglitol (n = 18), acarbose (n = 22), voglibose (n = 19) or control (n = 22) groups. Glycemic control (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, BMI, serum insulin, serum lipids (low-density lipoprotein and high-density lipoprotein cholesterol, and triacylglycerols) and adipocytokines (leptin and adiponectin) were evaluated every 4 weeks for 12 weeks. Results: In the miglitol group, HbA1c was improved significantly from the baseline at all points. The changes in HbA1c at 8 and 12 weeks from baseline were greater in the miglitol group than the control group. The voglibose group showed significant improvements in HbA1c at 12 weeks. Bodyweight and BMI were decreased significantly in the miglitol group. In addition, significant correlations were observed between the decrements in HbA1c and bodyweights over 12 weeks in the miglitol (r = 0.759, P < 0.001) and voglibose groups (r = 0.667, P = 0.002). Serum lipid and adipocytokine levels were not altered in any groups. Conclusions: αGIs, especially miglitol, can effectively control blood glucose and bodyweight in obese type 2 diabetes. This study was registered with UMIN (no. UMIN000006465).

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
publishing date
type
Contribution to journal
publication status
published
keywords
Bodyweight, Type 2 diabetes mellitus, α-Glucoseidase inhibitor
in
Journal of Diabetes Investigation
volume
5
issue
2
pages
206 - 212
publisher
Wiley-Blackwell
external identifiers
  • scopus:84896491587
ISSN
2040-1116
DOI
10.1111/jdi.12135
language
English
LU publication?
no
id
9be99396-199d-40bc-ac3c-7dc72b06d247
date added to LUP
2017-08-23 20:01:31
date last changed
2017-11-12 04:34:38
@article{9be99396-199d-40bc-ac3c-7dc72b06d247,
  abstract     = {<p>Aims/Introduction: α-Glucosidase inhibitors (αGIs) are widely used for the primary treatment of type 2 diabetes. We compared the clinical effects of three αGIs (miglitol, acarbose and voglibose) in patients with obese type 2 diabetes. Materials and Methods: Japanese patients (n = 81) with obese type 2 diabetes (body mass index [BMI] ≥25 kg/m<sup>2</sup>) were enrolled in this multicenter, open-label study. The participants were randomized into the miglitol (n = 18), acarbose (n = 22), voglibose (n = 19) or control (n = 22) groups. Glycemic control (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, BMI, serum insulin, serum lipids (low-density lipoprotein and high-density lipoprotein cholesterol, and triacylglycerols) and adipocytokines (leptin and adiponectin) were evaluated every 4 weeks for 12 weeks. Results: In the miglitol group, HbA1c was improved significantly from the baseline at all points. The changes in HbA1c at 8 and 12 weeks from baseline were greater in the miglitol group than the control group. The voglibose group showed significant improvements in HbA1c at 12 weeks. Bodyweight and BMI were decreased significantly in the miglitol group. In addition, significant correlations were observed between the decrements in HbA1c and bodyweights over 12 weeks in the miglitol (r = 0.759, P &lt; 0.001) and voglibose groups (r = 0.667, P = 0.002). Serum lipid and adipocytokine levels were not altered in any groups. Conclusions: αGIs, especially miglitol, can effectively control blood glucose and bodyweight in obese type 2 diabetes. This study was registered with UMIN (no. UMIN000006465).</p>},
  author       = {Sugihara, Hitoshi and Nagao, Mototsugu and Harada, Taro and Nakajima, Yasushi and Tanimura-Inagaki, Kyoko and Okajima, Fumitaka and Tamura, Hideki and Inazawa, Takeshi and Otonari, Takatoshi and Kawakami, Masanobu and Oikawa, Shinichi},
  issn         = {2040-1116},
  keyword      = {Bodyweight,Type 2 diabetes mellitus,α-Glucoseidase inhibitor},
  language     = {eng},
  number       = {2},
  pages        = {206--212},
  publisher    = {Wiley-Blackwell},
  series       = {Journal of Diabetes Investigation},
  title        = {Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes},
  url          = {http://dx.doi.org/10.1111/jdi.12135},
  volume       = {5},
  year         = {2014},
}